New perspectives in the management of small cell lung cancer

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Pangua, Cristina
• dc.contributor.author Rogado, Jacobo
• dc.contributor.author Serrano-Montero, Gloria
• dc.contributor.author Belda, José
• dc.contributor.author Álvarez Rodríguez, Beatriz
• dc.contributor.author Torrado, Laura
• dc.contributor.author Rodríguez de Dios, Núria
• dc.contributor.author Mielgo-Rubio, Xabier
• dc.contributor.author Trujillo-Reyes, Juan Carlos
• dc.contributor.author Couñago, Felipe
• dc.date.accessioned 2023-02-17T07:04:59Z
• dc.date.available 2023-02-17T07:04:59Z
• dc.date.issued 2022
• dc.description.abstract The treatment of small cell lung cancer (SCLC) is a challenge for all specialists involved. New treatments have been added to the therapeutic armamentarium in recent months, but efforts must continue to improve both survival and quality of life. Advances in surgery and radiotherapy have resulted in prolonged survival times and fewer complications, while more careful patient selection has led to increased staging accuracy. Developments in the field of systemic therapy have resulted in changes to clinical guidelines and the management of patients with advanced disease, mainly with the introduction of immunotherapy. In this article, we describe recent improvements in the management of patients with SCLC, review current treatments, and discuss future lines of research.
• dc.format.mimetype application/pdf
• dc.identifier.citation Pangua C, Rogado J, Serrano-Montero G, Belda-Sanchís J, Álvarez Rodríguez B, Torrado L, Rodríguez De Dios N, Mielgo-Rubio X, Trujillo JC, Couñago F. New perspectives in the management of small cell lung cancer. World J Clin Oncol. 2022 Jun 24;13(6):429-47. DOI: 10.5306/wjco.v13.i6.429
• dc.identifier.doi http://dx.doi.org/10.5306/wjco.v13.i6.429
• dc.identifier.issn 2218-4333
• dc.identifier.uri http://hdl.handle.net/10230/55814
• dc.language.iso eng
• dc.publisher Baishideng Publishing Group
• dc.relation.ispartof World J Clin Oncol. 2022 Jun 24;13(6):429-47
• dc.rights The Author(s) 2022. Published by Baishideng Publishing Group Inc. Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri https://creativecommons.org/Licenses/by-nc/4.0/
• dc.subject.keyword Atezolizumab
• dc.subject.keyword Durvalumab
• dc.subject.keyword Immunotherapy
• dc.subject.keyword Prophylactic cranial irradiation
• dc.subject.keyword Small cell lung cancer
• dc.subject.keyword Stereotactic body radiotherapy
• dc.subject.keyword Whole-brain radiotherapy
• dc.title New perspectives in the management of small cell lung cancer
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion